Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
01/16/2018 01/17/2018 01/18/2018 01/19/2018 01/22/2018 Date
13.84(c) 13.59(c) 13.74(c) 14.2(c) 14.365 Last
1 471 918 1 417 152 538 740 1 428 876 639 657 Volume
-3.32% -1.81% +1.10% +3.35% +1.16% Change
More quotes
Financials (€)
Sales 2017 247 M
EBIT 2017 41,5 M
Net income 2017 25,9 M
Debt 2017 103 M
Yield 2017 -
Sales 2018 329 M
EBIT 2018 68,7 M
Net income 2018 41,4 M
Debt 2018 98,5 M
Yield 2018 -
P/E ratio 2017 74,74
P/E ratio 2018 48,14
EV / Sales2017 8,89x
EV / Sales2018 6,66x
Capitalization 2 095 M
More Financials
Company
Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies.It operates through the EVT Execute and EVT Innovate segments.The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes... 
More about the company
Surperformance© ratings of Evotec AG
Trading Rating : Investor Rating :
More Ratings
Latest news on EVOTEC AG
01/19 EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
01/10 EVOTEC : Apeiron, Evotec to get 3 mn milestone payment from Sanofi in immuno-onc..
01/08 EVOTEC : and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with Sa..
01/08 EVOTEC : And apeiron achieve first milestone in immuno-oncology alliance with sa..
01/05 EVOTEC : to attend upcoming investor conferences
01/03 EVOTEC : to Attend Upcoming Investor Conferences
01/03 EVOTEC : to attend upcoming investor conferences
01/03 EVOTEC : To attend upcoming investor conferences
2017 EVOTEC AG : Release according to Article 26, Section 1 of the WpHG [the German S..
2017 EVOTEC AG : Release according to Article 26, Section 1 of the WpHG [the German S..
More news
Sector news : Biotechnology & Medical Research - NEC
08:48a Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion
08:48a Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion
08:48a SANOFI : Nears Deal for Bioverativ -- WSJ
08:47a Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion
07:47a SANOFI : to Acquire Bioverativ for $11.6 Billion
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on EVOTEC AG 
EVOTEC AG - 2017
A good level to buy
BUY
More Strategies
Latest Tweets
01/19Evotec AG: Release according to Article 40, Section 1 of the WpHG [the German.. 
01/08Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with S.. 
01/08APEIRON and Evotec Achieve First Milestone in Immuno-oncology Alliance with S.. 
01/08Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with S.. 
01/08Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with S.. 
More tweets
Qtime:36
News from SeekingAlpha
2017 Evotec enters into research collaboration with CRTD to discover therapies for..
2017 Evotec (EVTCY) Presents At Jefferies 2017 London Healthcare Conference - Slid..
2017 Evotec's (EVOTF) CEO Werner Lanthaler on Q3 2017 Results - Earnings Call Tran..
2017 MY JOURNEY TO FINANCIAL INDEPENDENCE : 85-Stock October Portfolio Update - Buyin..
2017 Evotec AG ADR 2017 Q3 - Results - Earnings Call Slides
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 19,0 €
Spread / Average Target 34%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG5.19%2 560
CELLTRION, INC.--.--%33 774
IQVIA HOLDINGS INC2.37%21 423
LONZA GROUP0.76%20 876
INCYTE CORPORATION-4.65%19 660
ALNYLAM PHARMACEUTICALS, INC.-1.42%12 275